Resveratrol to Enhance Vitality and Vigor in Elders
Last updated on April 2022Recruitment
- Recruitment Status
- Completed
- Estimated Enrollment
- 60
Inclusion Criteria
- Willingness to undergo all testing procedures.
- Age 65 years and older;
- Moderate to high functioning (i.e. a summary score of 4 - 10 on the Short Physical Performance Battery [SPPB]);
- ...
- Willingness to undergo all testing procedures.
- Age 65 years and older;
- Moderate to high functioning (i.e. a summary score of 4 - 10 on the Short Physical Performance Battery [SPPB]);
- Ability to understand study procedures and to comply with them for the entire length of the study;
- Body Mass Index (BMI) range: 20-39.9 kg/m2;
Exclusion Criteria
- Acute febrile illness in past 2 months;
- Recent bacterial/viral infection (< 2 weeks);
- High blood pressure (i.e. ≥ 140/90 mm Hg but ≤ 160/90) at the screening visit;
- ...
- Acute febrile illness in past 2 months;
- Recent bacterial/viral infection (< 2 weeks);
- High blood pressure (i.e. ≥ 140/90 mm Hg but ≤ 160/90) at the screening visit;
- Major surgery or hip/knee replacement (< 6 months).
Summary
- Conditions
- Mitochondrial Function
- Physical Function
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Supportive Care
Participation Requirements
- Age
- Between 65 years and 125 years
- Gender
- Both males and females
Description
An initial telephone screening indicated that the subject may be eligible to participate in the study. The first study visit ("Screening visit") will further determine if the subject is eligible to participate. Should the subject be eligible to participate in the study, the subject will be asked to ...
An initial telephone screening indicated that the subject may be eligible to participate in the study. The first study visit ("Screening visit") will further determine if the subject is eligible to participate. Should the subject be eligible to participate in the study, the subject will be asked to participate in a daily resveratrol or placebo supplementation program for approximately 90 days. The subject will also be asked to return to the clinic for two additional assessment visits to monitor his/her safety and measure study results. Details regarding the tests to be conducted during this screening visit and other study visits are described below. Visits will take place at the University of Florida Institute on Aging (IOA). The Screening Visit is approximately 1.5 to 2 hours and will include: Blood Draw: The subject is asked to fast before the appointment because blood will be collected during this visit. The investigator will collect approximately 2 tablespoons of blood. The purpose of this blood draw is to determine levels of certain compounds in the subject's blood that will help determine eligibility. Questionnaires: The subject will be asked questions about medical history and medications as well as mood and will also be asked to complete a short test of memory and reasoning. Physical Measurements: measurements of the subject's height, body weight, waist circumference, pulse, and blood pressure. Physical Exam: A licensed health care provider will perform a brief physical exam to determine if it is safe to continue with the study. This exam will include a review of medical history, medications, and measurement of height, blood pressure, radial pulse, weight, and waist circumference. Tests of physical performance: The subject will be asked to complete tests of physical ability that include: Walking at the usual pace for a distance of 13 feet (4 meters) two (2) separate times The subject will be asked to go from a standing to a sitting position, without using their arms. If the subject is able to perform this task, then they will be asked to stand up from and sit down on chair five (5) times as fast as possible. Maintaining balance while standing in three (3) different positions Baseline Visit 1: Should the subject be eligible for the study, they will be asked to return to the clinic for the first baseline study visit. This visit is expected to take 2 to 3 hours and will include: Measurement of pulse and blood pressure Measurement of body weight and waist circumference Collection of fasting blood samples Questions about the subject's health Tests of physical performance, including: Walking as fast and far as the subject can for 6 minutes Walking at subject's usual pace for a distance of 13 feet (4 meters) two (2) separate times Standing from a sitting position, without using their arms. If the subject is able to perform this task, then they will be asked to stand up from and sit down on chair five (5) times as fast as possible. Maintaining balance while standing in three (3) different positions. Assessment of lower-body muscle strength and endurance Physical Activity Monitor: The subject will also be asked to wear an armband physical activity monitor during a typical seven day period to assess baseline physical activity habits. The monitor will be returned at Baseline Visit 2. Baseline Visit 2 will take approximately 2 hours and will include: Measurement of pulse and blood pressure before procedure Muscle Tissue Sample: The procedure to collect muscle samples will be performed by a licensed healthcare provider with experience conducting the procedure. The procedure includes numbing a small area on the thigh with a local anesthetic and then using a needle about the size of a pen to collect a small amount of muscle tissue approximately equal to the size of the head of a pencil eraser. After the tissue sample is taken, the subject will receive detailed instruction on how to care for the incision site. Several follow-up phone assessments will be made inquiring about any problems that the subject may be experiencing related to the procedure. Measurement of pulse and blood pressure after procedure Randomization: Subjects who are eligible and safe to continue with the study, will be randomly assigned to one of three conditions: (1) resveratrol (1000 mg/day) (2) resveratrol (1500 mg/day) or (3) placebo (vegetable cellulose). The subject will be provided with a supply of the study drug capsules of at least 30 days and will be asked to return any remaining study drug capsules to the clinic at the next appointment. Subjects will be asked to orally consume one study drug capsule following each main meal (i.e. breakfast, lunch and dinner) with a glass of water. 30-Day & 60-Day Visits last approximately 1 hour and include: Collection of fasting blood samples Measurement of pulse and blood pressure Measurement of weight and waist circumference Update medical history and ask questions about any adverse experiences the subject may have had since the last visit Counting of any remaining study drug capsules that were not taken since last visit Providing the subject with study drug capsules needed until the next study visit 90-Day Visit 1 is similar to the Baseline 1 visit and will last approximately 2-3 hours. This visit includes: Measurement of pulse and blood pressure Measurement of body weight and waist circumference Collection of fasting blood samples Update medical history and ask questions about any adverse experiences the subject may have had since last visit Counting of any remaining study drug capsules that were not taken since last visit Tests of physical performance, including: Walking as fast and far as possible for 6 minutes Walking at usual pace for a distance of 13 feet (4 meters) two (2) separate times Standing from a sitting position, without using arms. If the subject is able to perform this task, he/she will be to stand up from and sit down on chair five (5) times as fast as possible. Maintaining balance while standing in three (3) different positions. Assessment of lower-body muscle strength and endurance The subject will receive an armband physical activity monitor to wear for seven days, and will be asked to return this monitor at the 90-Day Visit 2. 90-Day Visit 2 will be similar to the Baseline 2 visit and will last approximately 1.5 to 2 hours. Procedure to collect muscle tissue sample (as described in Baseline 2) Counting of any remaining study drug capsules that were not taken since last visit. Follow-Up 10-Day & 30-Day Visits are approximately 30 minutes to 1 hour Measurement of pulse and blood pressure Collection of fasting blood samples Update medical history and ask questions about any adverse experiences the subject may have had since last visit
Inclusion Criteria
- Willingness to undergo all testing procedures.
- Age 65 years and older;
- Moderate to high functioning (i.e. a summary score of 4 - 10 on the Short Physical Performance Battery [SPPB]);
- ...
- Willingness to undergo all testing procedures.
- Age 65 years and older;
- Moderate to high functioning (i.e. a summary score of 4 - 10 on the Short Physical Performance Battery [SPPB]);
- Ability to understand study procedures and to comply with them for the entire length of the study;
- Body Mass Index (BMI) range: 20-39.9 kg/m2;
Exclusion Criteria
- Acute febrile illness in past 2 months;
- Recent bacterial/viral infection (< 2 weeks);
- High blood pressure (i.e. ≥ 140/90 mm Hg but ≤ 160/90) at the screening visit;
- ...
- Acute febrile illness in past 2 months;
- Recent bacterial/viral infection (< 2 weeks);
- High blood pressure (i.e. ≥ 140/90 mm Hg but ≤ 160/90) at the screening visit;
- Major surgery or hip/knee replacement (< 6 months).
Tracking Information
- NCT #
- NCT02123121
- Collaborators
- National Center for Complementary and Integrative Health (NCCIH)
- Office of Dietary Supplements (ODS)
- Investigators
- Principal Investigator: Stephen D. Anton, Ph.D. University of Florida
- Stephen D. Anton, Ph.D. University of Florida